Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ESR-15-11199 | Other Identifier | AstraZeneca |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |
This is a single-arm non-interventional cohort study. This study is to describe the contemporary use of ticagrelor in a "real-world" setting, to reflect its acceptance and patients' compliance, and to observe its one-year safety in patients with acute coronary syndrome in Fuwai Hospital.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| the use of ticagrelor in hospital |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with switching between clopidogrel and ticagrelor | 12 months | |
| Number of participants with switching between clopidogrel and ticagrelor without a reloading dose | 12 months | |
| Number of Participants with discontinuation of P2Y12 receptor antagonist | 12 months | |
| Number of Participants with ticagrelor combined with other anticoagulants | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Cardiovascular Mortality, Myocardial Infarction(MI), Ischemic Stoke | composite incidence Myocardial infarction is defined and subclassified in accordance with ACC/AHA/ESC third universal definition of myocardial infarction Ischemic stroke: an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction, defined by at least one of the following:
Hemorrhage may be a consequence of ischemic stroke. In this situation, the stroke is an ischemic stroke with hemorrhagic transformation and not a hemorrhagic stroke. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
This study will include more than 1200 ACS patients using ticagrelor in Fuwai hospital from May 2016 to May 2017.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hongbing Yan, MD | Contact | +8610-88322287 | yanhongbingsuifang@163.com | |
| Juan Liu, MD | Contact | +8610-88322287 | tifuliu@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Hongbing Yan, MD | Chinese Academy of Medical Sciences, Fuwai Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fuwai Hospital | Recruiting | Beijing | Beijing Municipality | 100000 | China |
Not provided
| ID | Term |
|---|---|
| D054058 | Acute Coronary Syndrome |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 12 months |
| Number of bleeding event will be recorded (defined in accordance with PLATO definition) | 12 months |